A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

Brief description of study

The purpose of the study is to determine the safety and efficacy of the treatments: AB928, a novel adenosine receptor blocker, plus zimberelimab, an anti-PD1 antibody, alone or in combination with a standard of care (enzalutamide, docetaxel) or AB928 plus AB680, a novel CD73 inhibitor, with or without zimberelimab. The investigational drugs are AB928, zimberelimab, and AB680. These drugs have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s19-01947
ClinicalTrials.gov Identifier: NCT04381832
Principal Investigator: David R. Wise.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.